Anaesthesia and Parkinson's disease: How to manage with new therapies?

Current Opinion in Anaesthesiology

Volumn 22, Issue 3, 2009, Pages 419-424

  Kalenka, Armin ^a   Schwarz, Anke ^a  

^a University Medical Center Mannheim   (Georgia)

Author keywords

Anaesthesia; Complications; Deep brain stimulation; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXMEDETOMIDINE; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FENTANYL; HYDRALAZINE; INHALATION ANESTHETIC AGENT; KETAMINE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MORPHINE; OPIATE; PROPOFOL; RASAGILINE; ROTIGOTINE; SELEGILINE; THIOPENTAL; TOLCAPONE; URAPIDIL;

ADJUVANT THERAPY; AGITATION; AKINESIA; ANESTHESIA; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; CLINICAL FEATURE; COMPULSION; CRANIOTOMY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSKINESIA; GENERAL ANESTHESIA; HALLUCINATION; HEART RHYTHM; HUMAN; HYPERPYREXIA; HYPERTENSION; HYPOTENSION; MUSCLE RIGIDITY; NAUSEA; NEUROSURGERY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SWEATING; UNSPECIFIED SIDE EFFECT; VOMITING; WAKEFULNESS;

ANESTHESIA; ANTIPARKINSON AGENTS; DRUG INTERACTIONS; ELECTRODES, IMPLANTED; HUMANS; INTRAOPERATIVE CARE; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; POSTOPERATIVE CARE;

EID: 67649549930     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32832a4b31     Document Type: Review

References (48)

1. de Lau LML, Giesbergen PCLM, de Rijk MC, et al. Incidence of parkinsonism and Parkinson disease in a general population:The Rotterdam Study. Neurology 2004;63:1240-1244.
2. Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001; 57:1687-1694.
3. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71:474-480.
4. Lang AE, Lozano AM. Parkinson's disease - first of two parts. N Engl J Med 1998; 339:1044-1053.
5. Vitek J, Bakay R. The role of pallidotomy in Parkinson's disease and dystonia. Curr Opin Neurol 1997; 10:332-339.
6. Benabid A, Pollak P, Louveau A, et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50:344-346.
7. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33-39.
8. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: Initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58:11-17.
9. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007; 53:214-222.
10. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008; 359:2468-2476.
11. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008; 22: 563-587.
12. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 2003; 12:1335- 1352.
13. Nicholson G, Pereira AC, Hall GM. Parkinson's disease and anaesthesia. Br J Anaesth 2002; 89:904-916.
14. Burton DA, Nicholson G, Hall GM. Anaesthesia in elderly patients with neurodegenerative disorders. Drugs Aging 2004; 21:229-242.
15. Korczyn AD, Reichmann H, Boroojerdi B, et al.Rotigotine transdermal system for perioperative administration. J Neural Transm 2007; 114:219-221.
16. Kumar R, Lozano A, Kim Y, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998; 51:850-855.
17. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56: 548-551.
18. Deuschl G, Schade-Brittinger C, Krack P, et al. A Randomized trial of deep- brain stimulation for Parkinson's disease. N Engl J Med 2006; 355:896-908.
19. Krack P, Batir A, Van Blercom N, et al.Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349:1925-1934.
20. Peppe A, Pierantozzi M, Bassi A, et al.Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. J Neurosurg 2004; 101:195-200.
21. Lang A, Houeto J-L, Krack P, et al.Deep brain stimulation: preoperative issues. Mov Disord 2006; 21 :S171-S196.
22. Lang A, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002; 17:S94-S101.
23. Machado A, Rezai A, Kopell B, et al.Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management. Mov Disord 2006; 21 (Suppl 14):S247-S258.
24. Watson R, Leslie K. Nerve blocks versus subcutaneous infiltration for stereotactic frame placement. Anesth Analg 2001; 92:424-427.
25. Gumprecht H, Widenka D, Lumenta C. BrainLab VectorVision Neuronaviga- tion System: technology and clinical experiences in 131 cases. Neurosurgery 1999; 44:97-105.
26. Rezai A, Kopell B, Gross R, et al. Deep brain stimulation for Parkinson's disease: surgical issues. Mov Disord 2006; 21:S197-S218.
27. Houeto J-L, Welter M-L, Bejjani P-B, et al. Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. Arch Neurol 2003; 60:690- 694.
28. Maltete D, Navarro S, Welter M-L, et al.Subthalamic stimulation in Parkinson disease: with or without anaesthesia? Arch Neurol 2004; 61:390-392.
29. Guridi J, Rodriguez-Oroz M, Lozano A, et al.Targeting the basal ganglia for deep brain stimulation in Parkinson's disease. Neurology 2000; 55 (12 Suppl 6):S21-S28.
30. Tabbal S, Revilla F, Mink J, et al.Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraoperative mapping for treatment of Parkinson's disease. Neurosurgery 2007; 61 (Suppl 3):119- 127.
31. Seijo FJ, Alvarez-Vega MA, Gutierrez JC, et al. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochirurg 2007; 149:867-876. The largest study analysed 272 procedures and found complications in up to 30% of patients. Aborted procedures amounted to 5.14% of all procedures, misplaced leads 2.2%, intracranial haemorrhage 3.3%, seizures 4.7%, hardware complications 1.8% and other complications 5.1%.
32. Schubert A, Deogaonkar A, Lotto M, et al. Anaesthesia for minimally invasive cranial and spinal surgery. J Neurosurg Anesthesiol 2006; 18:47-56.
33. Khatib R, Ebrahim Z, Rezai A, et al.Perioperative events during deep brain stimulation: the experience at Cleveland clinic. J Neurosurg Anesthesiol 2008; 20:36-40.
34. Skucas AP, Artru AA. Anesthetic complications of awake craniotomies for epilepsy surgery. Anesth Analg 2006; 102:882-887.
35. Israel Z, Hassin-Baer S. Subthalamic stimulation for Parkinson's disease. Isr Med Assoc J 2005; 7:458-463.
36. Teräväinen H, Huttunen J, Larsen T. Selective adrenergic beta-2-receptor blocking drug, ICI-118.551, is effective in essential tremor. Acta Neurol Scand 1986; 74:34-37.
37. Gorgulho A, De Salles AA, Frighetto L, Behnke E. Incidence of hemorrhage associated with electrophysiological studies performed using macroelec- trodes and microelectrodes in functional neurosurgery. J Neurosurg 2005; 102:888-896.
38. Rozet I, Muangman S, Vavilala MS, et al. Clinical experience with dexmede- tomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg 2006; 103:1224-1228.
39. Krauss JK, Akeyson EW, Giam P, et al. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg 1996; 83:420-422.
40. Yamada K, Goto S, Kuratsu J, et al. Stereotactic surgery for subthalamic nucleus stimulation under general anaesthesia: a retrospective evaluation of Japanese patients with Parkinson's disease. Parkinsonism Relat Disord 2007; 13:101-107.
41. Lefaucheur J, Gurruchaga J, Pollin B, et al. Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multiunit recordings but not with the type of anaesthesia. Eur Neurol 2008; 60:186-199.
42. Schulz U, Keh D, Barner C, et al. Bispectral index monitoring does not improve anaesthesia performance in patients with movement disorders undergoing deep brain stimulating electrode implantation. Anesth Analg 2007; 104:1481-1487.
43. Nordera GP, Mesiano T, Durisotti C, et al.Six years' experience in deep brain stimulation in Parkinson's disease: advantages and limitations of use of neurophysiological intraoperative microreading. Neurol Sci 2003; 24:194- 1194.
44. Hertel F, Ziichner M, Weimar I, et al.Implantation of electrodes for deep brain stimulation of the subthalamic nucleus in advanced Parkinson's disease with the aid of intraoperative microrecording under general anaesthesia. Neuro-surgery 2006; 59:E1138.
45. Lin S-H, Chen T-Y, Lin S-Z, et al.Subthalamic deep brain stimulation after anesthetic inhalation in Parkinson disease: a preliminary study. J Neurosurg 2008; 109:238-244.
46. Deuschl G, Herzog J, Kleiner-Fisman G, et al.Deep brain stimulation: post-operative issues. Mov Dis 2006; 21 :S219-S237.
47. Herzog J, Volkmann J, Krack P, et al.Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Dis 2003; 18:1332-1337.
48. Dagtekin O, Berlet T, Gerbershagen HJ, et al.Anaesthesia and deep brain stimulation: postoperative akinetic state after replacement of impulse generators. Anesth Analg 2006; 103:784.